Cargando…

Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension

BACKGROUND: Peripheral blood mononuclear cells (PBMCs) play an important role in the pathogenesis of pulmonary arterial hypertension (PAH). However, the specific roles of PBMCs in the development and progression of idiopathic PAH (IPAH) have not been fully understood. METHODS: Here, differentially e...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Wenjun, Su, Xi, Chen, Lingdan, Liu, Chunli, Lu, Wenju, Wang, Tao, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724678/ https://www.ncbi.nlm.nih.gov/pubmed/34981661 http://dx.doi.org/10.14814/phy2.15101

Ejemplares similares

BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Chen, Lingdan, et al.
Publicado: (2020)

Positron Emission Tomography: A Novel Approach to Detect Pulmonary Artery Hypertension at the Early Stage?
por: Tang, Ruidi, et al.
Publicado: (2020)

TIMP-1: A Circulating Biomarker for Pulmonary Hypertension Diagnosis Among Chronic Obstructive Pulmonary Disease Patients
por: He, Wenjun, et al.
Publicado: (2022)

Integrated Bioinformatic Analysis Reveals TXNRD1 as a Novel Biomarker and Potential Therapeutic Target in Idiopathic Pulmonary Arterial Hypertension
por: Lin, Wenchao, et al.
Publicado: (2022)

Corrigendum: Integrated bioinformatic analysis reveals TXNRD1 as a novel biomarker and potential therapeutic target in idiopathic pulmonary arterial hypertension
por: Lin, Wenchao, et al.
Publicado: (2022)

The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension
por: Zeng, Wei-Jie, et al.
Publicado: (2012)

Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study
por: Chen, Yuqin, et al.
Publicado: (2019)

Correction to: Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study
por: Chen, Yuqin, et al.
Publicado: (2020)

Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension
por: Dong, Li, et al.
Publicado: (2014)

The roles of interleukins in perfusion recovery after peripheral arterial disease
por: Chen, Lingdan, et al.
Publicado: (2018)

Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension
por: Zhang, Rui, et al.
Publicado: (2020)

Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target
por: Wang, Ru, et al.
Publicado: (2023)

Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension
por: Wang, Kuo-Yang, et al.
Publicado: (2015)

Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
por: Casserly, Brian, et al.
Publicado: (2009)

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Furuya, Yoshiaki, et al.
Publicado: (2010)

Identification of Potential Biomarkers and Immune Infiltration Characteristics in Idiopathic Pulmonary Arterial Hypertension Using Bioinformatics Analysis
por: Zeng, Haowei, et al.
Publicado: (2021)

CD248 as a novel therapeutic target in pulmonary arterial hypertension
por: Xu, Tao, et al.
Publicado: (2020)

New Therapeutic Target for Pulmonary Arterial Hypertension
por: Yoon, Kyung Lim
Publicado: (2018)

Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study
por: Foris, Vasile, et al.
Publicado: (2023)

Pulmonary venous remodeling in COPD-pulmonary hypertension and idiopathic pulmonary arterial hypertension
por: Andersen, Kasper Hasseriis, et al.
Publicado: (2017)

Is It Still “Idiopathic”? Features of Autoimmunity in Idiopathic Pulmonary Arterial Hypertension
por: Frech, Tracy M., et al.
Publicado: (2022)

Apelin-APJ Signaling: a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Kim, Jongmin
Publicado: (2014)

Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review
por: Xiao, Ying, et al.
Publicado: (2020)

CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension
por: Tomaszewski, Michał, et al.
Publicado: (2022)

MicroRNA-133a impairs perfusion recovery after hindlimb ischemia in diabetic mice
por: Chen, Lingdan, et al.
Publicado: (2018)

Epistatic interactions in idiopathic pulmonary arterial hypertension
por: Vadapalli, Shivani, et al.
Publicado: (2012)

Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension
por: Huang, Yang, et al.
Publicado: (2021)

Transcription factors and potential therapeutic targets for pulmonary hypertension
por: Yang, Liu, et al.
Publicado: (2023)

Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension
por: Satoh, Kimio, et al.
Publicado: (2018)

Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension
por: Redel-Traub, Gabriel, et al.
Publicado: (2022)

Impact of right ventricular dyssynchrony on prognosis of patients with idiopathic pulmonary arterial hypertension
por: Cheng, Xiao-Ling, et al.
Publicado: (2019)

Immune-related potential biomarkers and therapeutic targets in coronary artery disease
por: Liu, Chaosheng, et al.
Publicado: (2023)

Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy
por: Malekmohammad, Majid, et al.
Publicado: (2019)

Integrated Bioinformatics Analysis Reveals Marker Genes and Potential Therapeutic Targets for Pulmonary Arterial Hypertension
por: Li, Aoqi, et al.
Publicado: (2021)

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension
por: Wang, Xiao-Jian, et al.
Publicado: (2020)

LCN2 is a new diagnostic biomarker and potential therapeutic target in idiopathic short stature
por: Liu, Xijuan, et al.
Publicado: (2022)

Pulmonary Vasculature: A Target for COVID-19
por: Chen, Lingdan, et al.
Publicado: (2021)

Biomarkers in Pulmonary Arterial Hypertension
por: Hojda, Silvana Elena, et al.
Publicado: (2022)

Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
por: Hiraishi, Keizo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orsqlkefgqb6jr8tqu06cd4i8v